Inivata Names New Chief Operations Officer
Cancer genomics company Inivata has appointed a clinical diagnostics veteran as its new chief operations officer.
You may also be interested in...
While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.